A pill for infertility: Oxolife’s non-hormonal oral drug raises embryo implantation rate, pregnancy rates and live birth rate in women undergoing IVF and ICSI, data being presented at ESHRE shows
A pill for infertility: Oxolife’s non-hormonal oral drug raises embryo implantation rate, pregnancy rates and live birth rate in women undergoing IVF and ICSI, data being presented at ESHRE shows
- Oxolife’s OXO-001 is a safe, first-in-class drug designed to improve the odds of an embryo embedding by making the endometrium more conducive to implantation
- Ongoing pregnancy rate was 10.6 percentage points higher in women who received OXO-001 than in those who received a placebo (46.3% for OXO-001 vs. 35.7% for placebo)
- Live birth rate was 6.9 percentage points higher (42.6% vs for OXO-001 vs. 35.7% for placebo)
- Results – from proof-of-concept Phase 2 double-blinded, randomised controlled trial in women up to 40 years of age who used donor eggs – to be published in Human Reproduction
- Oxolife plans pivotal Phase 3 study – to include women using own eggs